Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma

Neurology

Volumn 73, Issue 19, 2009, Pages 1526-1531

  Yu, J ^a   Deshmukh, H ^a   Gutmann, R J ^a   Emnett, R J ^a   Rodriguez, F J ^b   Watson, M A ^a   Nagarajan, R ^a   Gutmann, D H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; HOMEODOMAIN INTERACTING PROTEIN KINASE 2;

ARTICLE; ASTROCYTOMA; CARCINOGENESIS; CHILD; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE INSERTION; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS; PHENOTYPE; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL;

ASTROCYTOMA; CARRIER PROTEINS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA, NEOPLASM; GENE AMPLIFICATION; HUMANS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL;

EID: 72049096346     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c0664a     Document Type: Article

References (24)

1. Central Brain Tumor Registry of the United States. Primary Brain Tumors in the United States Statistical Report 2007-2008. CBTRUS: Hinsdale, IL; 2008.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. IARC: Lyon; 2007.
3. Listernick R, Darling C, Greenwald M, Strauss L, Char-row J. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 1995;127:718-722.
4. Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 optic pathway: Glioma Task Force. Ann Neurol 1997;41:143-149.
5. Gutmann DH, Donahoe J, Brown T, James CD, Perry A. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol 2000;26:361-367.
6. Kluwe L, Hagel C, Tatagiba M, et al. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astro-cytomas. J Neuropathol Exp Neurol 2001;60:917-920.
7. Wimmer K, Eckart M, Meyer-Puttlitz B, Fonatsch C, Pietsch T. Mutational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astro-cytomas. J Neuropathol Exp Neurol 2002;61:896-902.
8. Sanoudou D, Tingby O, Ferguson-Smith MA, et al. Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br J Cancer 2000;82:1218-1222.
9. White FV, Anthony DC, Yunis EJ, et al. Nonrandom chromosomal gains in pilocytic astrocytomas of childhood. Hum Pathol 1995;26:979-986.
10. Zattara-Cannoni H, Gambarelli D, Lena G, et al. Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet Cytogenet 1998;104:157-160.
11. Deshmukh H, Yeh TH, Yu J, et al. High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 2008;27:4745-4751.
12. Sharma MK, Watson MA, Lyman M, et al. Matrilin-2 expression distinguishes clinically relevant subsets of pilo-cytic astrocytoma. Neurology 2006;66:127-130.
13. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF (E600) in benign and malignant human tumours. Oncogene 2008;27:877-895.
14. Lanzilotta SG, Grammatica L, Paradiso A, Simone G. BRAF in papillary thyroid carcinoma. Cell Oncol 2997; 29:269-277.
15. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007;17:31-39.
16. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008;118: 1739-1749.
17. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG. Frequent gains at chromosome 7q34 involving BRAF in pilo-cytic astrocytoma. J Neuropathol Exp Neurol 2008;67: 878-887.
18. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68:8673-8677.
19. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004;20:1233-1240.
20. Partek Inc. Partek® Genomics SuiteTM. Partek Inc.; 2008 Affymetrix R Genotyping Console TM Software. Available at: www.affymetrix.com/products- services/software/specific/ genotyping-console-software.affx. Accessed March 12, 2009.
21. Nannya Y, Sanada M, Nakazaki K, et al. A robust algorithm for copy number detection using high-density oligo-nucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005;65:6071-6079.
22. Lift Genome Annotations. Available at: genome.ucsc.edu/ cgi-bin/hgLiftOver. Accessed March 12, 2009.
23. Sharma MK, Zehnbauer BA, Watson MA, Gutmann DH. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 2005;65: 1335-1336.
24. Janzarik WG, Kratz CP, Loges NT, et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 2997;38:61-63